Table 1.
All Subjects Selected Clinical and Clinicopathological1 Data (N=173)
| Hallucinators (n=50) | Non-hallucinators (n=123) | p-value | |
|---|---|---|---|
| Expired age | 80.8 (5.9) | 85.0 (7.3) | <.001 |
| Dementia or mild cognitive impairment | 47/50 (94%) | 108/123 (88%) | .23 |
| MMSE2 | 18.6 (8.7) | 20.0 (7.8) | .48 |
| Hoehn & Yahr stage | 3.5 (1.2) | 2.0 (1.9) | <.001 |
| Duration of Parkinson’s disease | 16.4 ± 7.3 | 11.9 ± 6.6 | .009 |
| Levodopa equivalent doses | 506 (486) | 256 (550) | 0.001 |
| Clinicopathological diagnoses1: | |||
| Alzheimer’s disease | 34/50 (68%) | 97/123 (79%) | .13 |
| Parkinson’s disease | 38/50 (76%) | 33/123 (27%) | <.001 |
| Alzheimer’s disease + Parkinson’s disease | 22/50 (44%) | 7/123 (6%) | <.001 |
| Dementia with Lewy bodies | 6/50 (12%) | 13/123 (11%) | .79 |
| Alzheimer’s disease + dementia with Lewy bodies | 6/50 (12%) | 13/123 (11%) | .79 |
| Alzheimer’s disease with Lewy bodies | 3/50 (6%) | 28/123 (23%) | .009 |
1
Clinicopathological diagnoses were established by pathological confirmation of clinical diagnoses made using published criteria for each disorder, as described in the text.
2
MMSE is the Mini-mental State Exam.
Mean values were compared using the two-sample t test. Frequencies of dichotomous characteristics were compared using the Pearson Chi-square test. The Fisher exact test was used instead if the minimum expected cell count was less than five.